PORTFOLIO
PORTFOLIO COMPANIES
MOLCURE Inc. (Exited)
COMPANY PROFILE
Designing highly functional antibodies for diseases without effective treatment
MOLCURE combines Next Generation Sequencing (NGS), bioinformatics and antibody engineering to develop a highly functional discovery platform Abtracer™. Abtracer™ eliminates inherent bias of conventional methods and creates highly functional antibodies for pharmaceutical development.
COMPANY STORY
Origin
Ryu Ogawa, the founder of Molcure, was striving to become a scientist at Keio University when he lost his father to cancer. This motivated him to establish a startup that enables the shortest path to cancer drug discovery and development.
Strength
By combining conventional methods for antibody production with a next-generation sequencer and Machine Learning, Molcure has developed a drug discovery platform that enables the acquisition of high-performance antibodies that could not be detected by existing methods.
UTEC’s value add
UTEC provides multifaceted support in the form of funding, introducing collaborators, designing business strategies, and introducing customers.
-
Proprietary antibody development platform : Abtracer.
